Cytokinetics CYTK PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's PP&E (net)?
- Cytokinetics (CYTK) reported PP&E (net) of $82.44M in Q1 2026.
- How has Cytokinetics's PP&E (net) changed year-over-year?
- Cytokinetics's PP&E (net) increased by 22.7% year-over-year, from $67.18M to $82.44M.
- What is the long-term trend for Cytokinetics's PP&E (net)?
- Over 5 years (2020 to 2025), Cytokinetics's PP&E (net) has grown at a 42.8% compound annual growth rate (CAGR), from $13.35M to $79.19M.
- What does PP&E (net) mean?
- The net value of the company's physical assets like buildings and equipment after accounting for wear and tear.
- How do you interpret PP&E (net)?
- An increase indicates capital expenditure on infrastructure, while a decrease suggests depreciation or asset disposal.
- How does PP&E (net) compare across companies?
- Biotech firms that outsource manufacturing typically have lower property and equipment balances than those with internal manufacturing capabilities.